Canceling the government-priced cheap discontinued drugs expected to return to the market

has been in place for more than a decade to manage the maximum retail price of drugsRecently, the National Development and Reform Commission and other departments issued "promoting drug price reform opinions", decided from June 1 to eliminate the majority of drugs government pricing, the actual price of drugs is mainly formed by market competitionCan the price of medicines be straightened out and the "drug-based medicine" situation can be broken and the burden of patients' expenses reduced?drug prices to remain basically stable cheap discontinued drugs are expected to return to the market
" the same chemical composition of the drug, there are 100 pharmaceutical plants in productionTo liberalize the maximum price of drugs, for these homogenized drugs, due to the role of market competition mechanism, not only will not easily increase prices, may also take the initiative to reduce prices"The director of the Management Research Centre at Hong Kong's Ai Libi Hospital, MrZhuang Yiqiang, saidalso pointed out that the original because of low prices, low profits and stop production of drugs, such as tetanus needles, the price may rise, but this is not a bad thingBecause manufacturers get the enthusiasm, some of the already delisted "orphan medicine" will return to the marketthe overall situation, there are many experts believe that in the current public hospital drug centralized bidding and procurement mechanism still exists, drug prices will not be substantial lyingthe drugs currently used in public hospitals, the local provincial centralized procurement management department of drugs unified bidding procurement, the final resulting tender price is the maximum price of drugs purchased by hospitalsHospitals can only increase the price by 15% on this basis, and can not exceed the maximum retail price of drugs stipulated by the NDRC, so the tender price has become a decisive factor affecting the price of drugson the day of the issue of the Opinion on Promoting Drug Price Reform, the relevant officials of the National Development and Reform Commission explained that the prices of drugs sold in hospitals would remain basically stable due to the constraints of the bidding and procurement mechanismplay the role of medical insurance control fee "inflated drug prices" problem is expected to alleviate thethe policy on drug prices have little impact, can we break the drug-based medicine? "'Play the role of health insurance control fee' is an important significance of this reform Cai Jiangnan, director of the Center for Medical Management and Policy Studies at China Europe International Business School, said, "The reform of the payment system, that is, the role of health care in price-setting, will be a breakthrough to eliminate the disadvantages of medicine and medicine." "
the industry now generally believethat that the direct cause of medicine-based medicine is the price distortion caused by price control Because of the low price of medical services, hospitals can not afford to maintain their operations by charging for medical services alone, and have to make up for them through the high profits from selling medicines " medical insurance is used to pay for drugs, but also to pay for medical services, if the future health insurance sector to participate in drug pricing, it is convenient to make reasonable adjustments to the price structure of the two, so as to promote the price of medical services technology to be raised, while the proportion of hospital medical income down, to achieve a long-term effect Cai Jiangnan said Zhu Hengpeng, deputy director of the Institute of Economic Research of the Chinese Academy of Social Sciences, , said bluntly: "In addition to the 15% of the drug rebates disclosed in hospitals, about 30% exist in the form of hidden rebates and rebates." The real abolition of medicine-based medicine, but also to eliminate that 30% of the hidden benefits "
Zhuang Yiqiang believes that, after the liberalization of drug prices, homogenized drugs in the market competition will have a trend of lower prices, corporate profits reduced, drug rebate space narrowed, drug prices are expected to ease the problem When prescribing drugs, doctors no longer choose who they give based on the rebates they give, but on who they actually need Zhu Hengpeng
, to break the comprehensive reform of the personnel system required by drug-based medicine, believes that the government's abolition of most drug pricing is the first step to get drugs to market pricing, which is of positive significance he added that if we want to completely eliminate the disadvantages of drug-based medicine, so that drugs to normal market pricing, but also need to touch the core issue of the medical system " the root of medicine is the monopoly position of public hospitals and the status of doctors' unit owners Zhu Hengpeng analysis, "in the provision of medical services to public institutions as the main body, and doctors are state-owned institutions, it is not possible to regulate and transparently open the income gap between doctors and other types of state-owned units, such as civil servants and teachers, it is impossible to make the price of medical services reflect the difference in the level of medical skills, more unlikely to liberalize the price of medical services, by the market itself according to the level of doctors pricing." At this time, the market will be hidden in a way, such as red envelopes, rebates, scalpers, to pay the doctor service market-oriented prices "
Cai Jiangnan holds a similar view He argues that if doctors are tied to a system that does not move freely, they will not be able to obtain the price of medical services that truly reflect their own value, as determined by the market In this case, it is difficult to put an end to over-checking and issuing large prescriptions to increase compensation Zhuang Yiqiang pointed out that drugs to reach the hands of ordinary people, its price will go through three administrative "leverage" adjustment, one is the National Development and Reform Commission to establish the maximum retail price of drugs, the other is the provincial drug centralized procurement management department of the unified tender price, three is the medical insurance reimbursement price "Now it's the first line of defense that's been opened up He said